What are the indications for using biologic therapies such as dupilumab, mepolizumab, benralizumab, or omalizumab in a patient with chronic sinus congestion, recurrent sinus infections, allergic sinusitis, and a persistently elevated peripheral eosinophil count of 280 cells/µL (greater than 150 cells/µL)?

Biologic Therapy Indications for Your Clinical Scenario

Based on your presentation—chronic sinus congestion, recurrent sinus infections, allergic sinusitis, and persistently elevated eosinophils (280 cells/µL, consistently >150)—you meet criteria for biologic therapy if you have chronic rhinosinusitis with nasal polyps (CRSwNP) that has failed adequate medical management with intranasal corticosteroids and/or prior sinus surgery. 1, 2

Key Diagnostic Requirements

Before considering biologics, you must have:

• Documented nasal polyps on endoscopy or CT imaging showing chronic rhinosinusitis
• Symptoms lasting ≥3 months including nasal congestion/obstruction, rhinorrhea, and/or smell dysfunction 2
• Evidence of Type 2 inflammation, which your elevated eosinophils (280 cells/µL) clearly demonstrate 2, 3

Critical caveat: Biologics are not currently indicated for allergic rhinitis alone or simple recurrent sinusitis without nasal polyps. 2 If you don't have documented nasal polyps, biologics are not appropriate regardless of your eosinophil count.

Specific Indications for Biologic Initiation

The 2023 Joint Task Force guidelines and 2025 European consensus recommend biologics for CRSwNP when you have: 1, 2

• Failed adequate trial of intranasal corticosteroids (at least 8-12 weeks)
• History of prior sinus surgery with persistent/recurrent disease, OR
• High disease severity with significantly impaired quality of life (SNOT-22 score typically >40)
• Need for repeated systemic corticosteroids (≥2 courses in past year or continuous use)
• Evidence of Type 2 inflammation (your eosinophil count of 280 qualifies) 2, 3

Which Biologic to Choose

For CRSwNP specifically, dupilumab demonstrates the strongest evidence for symptom improvement and quality of life benefits (mean SNOT-22 improvement of -19.91 points vs. placebo), followed by omalizumab (-16.09 points) and mepolizumab (-1.82 points for nasal symptoms). 1

Selection Algorithm Based on Your Profile:

Primary choice: Dupilumab 1, 2

• Most effective for CRSwNP across all outcomes
• Targets IL-4/IL-13 receptors
• Particularly beneficial with your elevated eosinophils
• Watch for: Conjunctivitis (occurs in ~2% of CRSwNP patients) 1

Alternative: Omalizumab if: 2, 4

• You have concurrent allergic asthma with elevated IgE
• You are a female planning pregnancy (most safety data available) 2
• Your total IgE is 30-700 IU/mL and body weight allows dosing per FDA tables 4
• Watch for: Anaphylaxis risk (0.09% in asthma patients) 1

Alternative: Mepolizumab if: 1, 2

• You have concurrent severe eosinophilic asthma requiring optimization
• Your eosinophils are markedly elevated (yours at 280 qualifies, but higher levels favor this choice)
• Less effective for smell improvement compared to dupilumab

Practical Implementation

Before starting any biologic: 2

1. Confirm nasal polyps via endoscopy (bilateral polyps required)
2. Document baseline SNOT-22 score and nasal polyp score
3. Check total IgE level (if considering omalizumab)
4. Ensure patient has tried and failed intranasal corticosteroids
5. Document prior surgeries if applicable

Monitoring response: 2, 5

• Assess at 4-6 months for initial response
• Reassess at 12 months for continued benefit
• Discontinue if no meaningful improvement in symptoms or quality of life

Important Caveats

Your eosinophil count of 280 cells/µL is elevated but not dramatically so. While this supports Type 2 inflammation, the decision for biologics hinges more on:

• Presence of actual nasal polyps (not just "sinusitis")
• Failure of standard medical therapy
• Impact on quality of life
• Prior surgical history 1, 3

If you have allergic rhinitis WITHOUT nasal polyps, biologics are not currently indicated, regardless of eosinophil levels. 2 Standard management would be intranasal corticosteroids, antihistamines, and allergen immunotherapy.

Cost considerations: Biologics require ongoing subcutaneous injections (every 2-4 weeks) and are significantly more expensive than surgery, even accounting for revision procedures. 6 Insurance authorization typically requires documented failure of medical therapy and/or surgery.